INS and type 2 diabetes mellitus: The observed reduction in HCC risk is likely attributable to the anti-inflammatory, metabolic, and immunomodulatory effects of GLP-1RAs. Current evidence suggests that GLP-1RAs may play a protective role in reducing HCC risk among individuals with T2DM, particularly when compared with insulin-based regimens.